The National Cancer Institute approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – NRG-HN008
Phase I Trial with Expansion Cohort of DNA-PK Inhibition and IMRT in Cisplatin-Ineligible Patients with Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
NRG Oncology
Gillison, Maura Lianne
(713) 792-6363
Phase I/II – 10384
A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination with Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma
City of Hope Comprehensive Cancer Center LAO
Khodadoust, Michael Siavash
(650) 725-6451
Phase II – 10371
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
National Cancer Institute LAO
Chen, A P
(240) 781-3320
Phase II – A222001
A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin versus Placebo for Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy
Alliance for Clinical Trials in Oncology
Stish, Bradley J.
(507) 538-6120
Phase II – S2007
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
SWOG
Brenner, Andrew Jacob
(210) 450-5936
Phase III – A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Alliance for Clinical Trials in Oncology
Wei, Xiao X.
(617) 632-4524
Phase III – URCC-19185
Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)
University of Rochester NCORP Research Base
Palesh, Oxana
(650) 725-7011
